...
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations
Shopping cart close
Scilex Holding Scilex Holding
  • About
    • Overview
    • Leadership
    • Board Of Directors
    • Our Culture
    • Gallery
  • Product Portfolio
    • Technology
    • Pipeline
    • ZTLido®
    • Elyxyb®
    • Gloperba®
    • Expanded Access Policy
  • Partners
  • Science
    • Medical information U.S.
    • Publications
  • Investors
    • Investors Overview
    • News & Events
    • Presentations
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
    • FAQs
  • Join Our Team
  • Contact Us
    • Contact Us
    • Locations

Blog

09 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 9, 2023
  • Posted by Ulisses

Read more

09 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 9, 2023
  • Posted by Ulisses

Read more

09 Feb
SEC FIlings

Current report

  • February 9, 2023
  • Posted by Ulisses

Read more

06 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 6, 2023
  • Posted by Ulisses

Read more

06 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 6, 2023
  • Posted by Ulisses

Read more

06 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 6, 2023
  • Posted by Ulisses

Read more

06 Feb
SEC FIlings

Current report

  • February 6, 2023
  • Posted by Jitendra

Read more

04 Feb
Press Release

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders

  • February 4, 2023
  • Posted by Jitendra
PALO ALTO, February 4, 2023 /Newswire/ -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), an innovative revenue-generating company focused...

Read more

03 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 3, 2023
  • Posted by Jitendra

Read more

03 Feb
SEC FIlings

Prospectus [Rule 424(b)(3)]

  • February 3, 2023
  • Posted by Jitendra

Read more

«‹910111213›»
Close
Recent Posts
  • scilex-no-pic
    Henry Ji, PhD
    August 21, 2025 No Comments
  • scilex-no-pic
    Stephen Ma
    August 21, 2025 No Comments
  • scilex-no-pic
    Jaisim Shah
    August 21, 2025 No Comments
  • scilex-no-pic
    Dorman Followwill 
    August 21, 2025 No Comments
  • Alexander Wu, PhD
    August 21, 2025 No Comments
scilex-holding-logo-white

Terms of Use  Privacy Policy  Contact

  • Follow us on Facebook
  • Follow us on LinkedIn
  • Contact us by email

©2025 Scilex Holding All Rights Reserved
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

Scroll To Top Sidebar
We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
Accept More info